Skip to main content
. 2021 Jun 23;49(6):03000605211021278. doi: 10.1177/03000605211021278

Table 5.

Adverse events reported in at least two patients (among all fidaxomicin-treated patients).

AE, n (%) Number of AEs Number of patients, N=296
Clostridium difficile infectiona 45 41 (13.9)
Drug ineffectiveb 14 13 (4.4)
General physical health deterioration 10 9 (3.0)
Death 8 8 (2.7)
Diarrhoea 4 4 (1.4)
Renal failure acute 4 4 (1.4)
Cardiac failure 3 3 (1.0)
Respiratory failure acute 3 3 (1.0)
Septic shock 3 3 (1.0)
Agranulocytosis 2 2 (0.7)
Lung disorder 3 2 (0.7)
Clostridium difficile colitis 2 2 (0.7)
Colitis 2 2 (0.7)
Intestinal obstruction 2 2 (0.7)
Rash 2 2 (0.7)
Respiratory distress 2 2 (0.7)
Respiratory distress syndrome, acute 2 2 (0.7)

aReported at any point during the study, regardless of treatment timing. bNo improvement in diarrhoea symptoms. AE, adverse event; n, number of patients with stated AEs; N, number of fidaxomicin-treated patients.